Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antaitavir Hasophate and Yiqibuvir in Chronic HCV
NCT05395416Phase 3Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jun 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of antaitavir hasophate in hepatitis C (HCV) (3 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Sustained Virologic Response at 12 Weeks and Adverse Events. Started Jun 2021; status: completed.
02
Drugs
antaitavir hasophate
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05395416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395416.